232 related articles for article (PubMed ID: 24583671)
1. Genotypic resistance profiles of HIV-2-treated patients in West Africa.
Charpentier C; Eholié S; Anglaret X; Bertine M; Rouzioux C; Avettand-Fenoël V; Messou E; Minga A; Damond F; Plantier JC; Dabis F; Peytavin G; Brun-Vézinet F; Ekouevi DK;
AIDS; 2014 May; 28(8):1161-9. PubMed ID: 24583671
[TBL] [Abstract][Full Text] [Related]
2. Survival among antiretroviral-experienced HIV-2 patients experiencing virologic failure with drug resistance mutations in Cote d'Ivoire West Africa.
Tchounga BK; Charpentier C; Coffie PA; Dabis F; Descamps D; Eholie SP; Ekouevi DK
PLoS One; 2020; 15(8):e0236642. PubMed ID: 32756581
[TBL] [Abstract][Full Text] [Related]
3. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of HIV-1 drug resistance among patients failing first-line ART in Monrovia, Liberia: a cross-sectional study.
Loubet P; Charpentier C; Visseaux B; Borbor A; Nuta C; Adu E; Chapplain JM; Baysah M; Tattevin P; Yazdanpanah Y; Descamps D
J Antimicrob Chemother; 2015; 70(6):1881-4. PubMed ID: 25698771
[TBL] [Abstract][Full Text] [Related]
5. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
[TBL] [Abstract][Full Text] [Related]
6. Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma.
Soulie C; Grudé M; Descamps D; Amiel C; Morand-Joubert L; Raymond S; Pallier C; Bellecave P; Reigadas S; Trabaud MA; Delaugerre C; Montes B; Barin F; Ferré V; Jeulin H; Alloui C; Yerly S; Signori-Schmuck A; Guigon A; Fafi-Kremer S; Haïm-Boukobza S; Mirand A; Maillard A; Vallet S; Roussel C; Assoumou L; Calvez V; Flandre P; Marcelin AG;
J Antimicrob Chemother; 2017 Aug; 72(8):2351-2354. PubMed ID: 28472307
[TBL] [Abstract][Full Text] [Related]
7. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H; Kelleher AD; Amin J; Emery S; Cooper DA;
Lancet HIV; 2015 Feb; 2(2):e42-51. PubMed ID: 26424460
[TBL] [Abstract][Full Text] [Related]
8. Genotypic human immunodeficiency virus type 1 drug resistance in highly active antiretroviral therapy-treated children in Abidjan, Côte d'Ivoire.
Chaix ML; Rouet F; Kouakoussui KA; Laguide R; Fassinou P; Montcho C; Blanche S; Rouzioux C; Msellati P
Pediatr Infect Dis J; 2005 Dec; 24(12):1072-6. PubMed ID: 16371868
[TBL] [Abstract][Full Text] [Related]
9. Virological efficacy and immunological recovery among Ethiopian HIV-1 infected adults and children.
Mulu A; Liebert UG; Maier M
BMC Infect Dis; 2014 Jan; 14():28. PubMed ID: 24422906
[TBL] [Abstract][Full Text] [Related]
10. Virological failure and HIV-1 drug resistance mutations among naive and antiretroviral pre-treated patients entering the ESTHER program of Calmette Hospital in Cambodia.
Barennes H; Guillet S; Limsreng S; Him S; Nouhin J; Hak C; Srun C; Viretto G; Ouk V; Delfraissy JF; Ségéral O
PLoS One; 2014; 9(8):e105736. PubMed ID: 25166019
[TBL] [Abstract][Full Text] [Related]
11. Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.
Cabrera C; Cozzi-Lepri A; Phillips AN; Loveday C; Kirk O; Ait-Khaled M; Reiss P; Kjaer J; Ledergerber B; Lundgren JD; Clotet B; Ruiz L;
Antivir Ther; 2004 Oct; 9(5):787-800. PubMed ID: 15535417
[TBL] [Abstract][Full Text] [Related]
12. Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch.
Johnston V; Cohen K; Wiesner L; Morris L; Ledwaba J; Fielding KL; Charalambous S; Churchyard G; Phillips A; Grant AD
J Infect Dis; 2014 Mar; 209(5):711-20. PubMed ID: 23943851
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety and predictive factors of virological success of a boosted amprenavir-based salvage regimen in heavily antiretroviral-experienced HIV-1-infected patients.
Clevenbergh P; Boulmé R; Kirstetter M; Dellamonica P
HIV Med; 2004 Jul; 5(4):284-8. PubMed ID: 15236618
[TBL] [Abstract][Full Text] [Related]
14. Second-line antiretroviral therapy failure and characterization of HIV-1 drug resistance patterns in children in Mali.
Sylla M; Dolo O; Maiga AI; Traore FT; Coulibaly YA; Togo J; Fofana DB; Dicko-Traore F; Doumbia S; Orsega S; Diallo S; Murphy RL; Calvez V; Marcelin AG
Arch Pediatr; 2019 Jul; 26(5):254-258. PubMed ID: 31307909
[TBL] [Abstract][Full Text] [Related]
15. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.
Prendergast A; Mphatswe W; Tudor-Williams G; Rakgotho M; Pillay V; Thobakgale C; McCarthy N; Morris L; Walker BD; Goulder P
AIDS; 2008 Jul; 22(11):1333-43. PubMed ID: 18580613
[TBL] [Abstract][Full Text] [Related]
16. Characterization of associations and development of atazanavir resistance after unplanned treatment interruptions.
Tinago W; O'Halloran JA; O'Halloran RM; Macken A; Lambert JS; Sheehan GJ; Mallon PW
HIV Med; 2014 Apr; 15(4):224-32. PubMed ID: 24215370
[TBL] [Abstract][Full Text] [Related]
17. Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients.
van der Ende ME; Prins JM; Brinkman K; Keuter M; Veenstra J; Danner SA; Niesters HG; Osterhaus AD; Schutten M
AIDS; 2003 Jul; 17 Suppl 3():S55-61. PubMed ID: 14565610
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of an affordable HIV-1 virological failure assay and antiretroviral drug resistance genotyping protocol.
Bronze M; Aitken SC; Wallis CL; Steegen K; Stuyver LJ; de Wit TF; Stevens W
J Virol Methods; 2013 Dec; 194(1-2):300-7. PubMed ID: 23994150
[TBL] [Abstract][Full Text] [Related]
19. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire.
Adjé-Touré CA; Cheingsong R; Garcìa-Lerma JG; Eholié S; Borget MY; Bouchez JM; Otten RA; Maurice C; Sassan-Morokro M; Ekpini RE; Nolan M; Chorba T; Heneine W; Nkengasong JN
AIDS; 2003 Jul; 17 Suppl 3():S49-54. PubMed ID: 14565609
[TBL] [Abstract][Full Text] [Related]
20. Construction, training and clinical validation of an interpretation system for genotypic HIV-1 drug resistance based on fuzzy rules revised by virological outcomes.
De Luca A; Vendittelli M; Baldini F; Di Giambenedetto S; Trotta MP; Cingolani A; Bacarelli A; Gori C; Perno CF; Antinori A; Ulivi G
Antivir Ther; 2004 Aug; 9(4):583-93. PubMed ID: 15456090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
